Humana Inc. (NYSE:HUM – Get Free Report) has been assigned an average rating of “Hold” from the twenty ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $293.3333.
Several analysts have weighed in on HUM shares. Bank of America boosted their price target on Humana from $285.00 to $312.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Wall Street Zen downgraded Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Evercore ISI assumed coverage on shares of Humana in a report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price target on the stock. Barclays decreased their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Mizuho set a $300.00 price objective on shares of Humana in a report on Friday.
Get Our Latest Report on Humana
Institutional Trading of Humana
Humana Stock Up 4.3%
NYSE:HUM opened at $295.96 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana has a twelve month low of $206.87 and a twelve month high of $315.35. The company has a market cap of $35.60 billion, a PE ratio of 22.71, a P/E/G ratio of 1.67 and a beta of 0.42. The company’s 50 day moving average is $276.06 and its two-hundred day moving average is $257.49.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the previous year, the firm posted $6.96 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts anticipate that Humana will post 16.47 EPS for the current year.
Humana Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s dividend payout ratio (DPR) is currently 27.17%.
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- Ride Out The Recession With These Dividend KingsĀ
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Exceptional Stocks to Build Long-Term Wealth
- What Investors Need to Know to Beat the Market
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.